Weight Loss for Urinary Incontinence
Weight loss should be strongly considered as an initial conservative treatment for urinary incontinence in overweight and obese women.[10] Randomized evidence comes from the PRIDE trial (2009 NEJM), and a large prospective bariatric cohort (LABS-2) supports it. ACOG PB 155 endorses it.[1][5][11] In a pooled PRIDE secondary analysis, women losing 5% to <10% of body weight had greater reductions in weekly urinary incontinence episodes than women who gained weight, without clear additional benefit at ≥10% loss.[23] The effect was clearer for stress than for urgency incontinence.[11][12][23] The 2015 Cochrane review rated evidence for weight-loss programs low quality.[6] A 2022 Cochrane overview found high-certainty evidence of greater cure or improvement immediately after treatment and moderate-certainty evidence at six months in analyses combining UI types; one 18-month analysis did not detect a between-group difference.[27]
For the broader SUI ladder see Female Stress Incontinence Database; for OAB / UUI see OAB / UUI Database. For the broader behavioral toolkit see Behavioral Therapy for Urinary Incontinence and Pelvic Floor PT.
Pathophysiology — Why Obesity Causes Incontinence
Obesity is associated with incontinence, and the mechanisms below have been proposed.[3][4]
Mechanical
- Increased intra-abdominal pressure (IAP). Central adiposity chronically elevates IAP, increasing bladder pressure and urethral mobility. When IAP exceeds urethral closure pressure during exertion, stress incontinence results.[3][4]
- Pelvic-floor overload. Chronic elevated pressure weakens endopelvic fascia, levator ani, and pudendal nerve over time, analogous to vaginal-delivery pelvic-floor injury.[4]
- Detrusor instability. Elevated IAP may also exacerbate detrusor overactivity, contributing to urgency incontinence.[5]
Metabolic
- Systemic inflammation. Visceral adipose tissue releases TNF-α, IL-6 and leptin, generating reactive oxygen species and oxidative stress, and alters collagen metabolism in pelvic-floor connective tissue.[3][4]
- Insulin resistance and diabetes. Established diabetes can impair bladder innervation, and marked hyperglycemia can cause osmotic polyuria. Among 1,957 overweight women with prediabetes in the Diabetes Prevention Program, weekly incontinence at a mean of 2.9 years was less prevalent after lifestyle intervention (38.3%) than after metformin (48.1%) or placebo (45.7%). Weight change explained most of the lower stress-UI prevalence; incident diabetes did not mediate the benefit.[21]
- Hormonal alterations. Obesity-related shifts in estrogen metabolism and adipokine signaling affect urethral or bladder function.[3]
Dose-response: BMI and incontinence risk
Each 5-unit BMI increase is associated with a 20–70% increase in UI risk, and the maximum effect rarely exceeds OR 4–5. The odds of incident incontinence over 5–10 years increase by about 30–60% per 5-unit BMI rise. The association may be stronger for SUI and mixed incontinence than for urgency incontinence.[10]
SUI vs UUI — Asymmetric Benefit
| Phenotype | Effect of weight loss | Source |
|---|---|---|
| Stress UI | Most consistent benefit. PRIDE 6-mo: 58% SUI reduction (vs 33% control); 12-mo: 65% vs 47% (p < 0.001) | PRIDE 6 mo[11]; 12 mo[22] |
| Urgency UI | Less consistent for mean episode counts: PRIDE 6-mo reduction was 42% vs 26% (p = 0.14), although ≥ 70% episode reduction favored intervention (p = 0.04); at 18 mo, ≥ 70% reduction also favored intervention (47% vs 34%, p = 0.03) | PRIDE 6 mo[11]; 18 mo[22] |
| Mixed UI | Included in PRIDE’s baseline-phenotype analysis; the total-episode treatment effect did not differ significantly across stress-predominant, urgency-predominant, and mixed groups (heterogeneity p = 0.75), but a mixed-only effect estimate was not reported | PRIDE 6 mo[11] |
A mechanical pathway through IAP has been proposed to explain the larger SUI effect. The mechanism of the urgency effect is unclear.
The PRIDE Trial — the Anchor RCT
PRIDE (Program to Reduce Incontinence by Diet and Exercise) randomized 338 overweight or obese women with ≥ 10 weekly incontinence episodes to an intensive 6-mo behavioral weight-loss program (n = 226) or structured education (n = 112).[11] Follow-up continued to 18 months.[11][22]
| Time | Weight loss (intervention) | Total UI reduction (intervention vs control) | SUI | UUI |
|---|---|---|---|---|
| 6 mo | 8.0% (7.8 kg) | 47% vs 28% (p = 0.01; UI data: 214 vs 90) | 58% vs 33% (p = 0.02) | 42% vs 26% (NS)[11] |
| 12 mo | 7.5% | Greater proportion with ≥ 70% reduction | 65% vs 47% (p < 0.001)[22] | — |
| 18 mo | 5.5% | No significant difference for SUI / total | NS | > 70% improvement favored intervention[22] |
At 18 months, average weight loss in the intervention group had fallen from 8.0% to 5.5%, and stress and total incontinence no longer differed between groups. The authors noted that improving weight-loss maintenance may provide longer-term benefit.[22]
Dose-Response — How Much Weight Loss Is Needed?
A secondary analysis of PRIDE pooled both arms and compared weight-loss categories with women who gained weight. Reductions in total weekly incontinence episodes at 6, 12 and 18 months were 11%, 31% and 40% with weight gain and 28%, 46% and 50% with a loss of less than 5%.[23]
| Magnitude | Effect |
|---|---|
| ≥ 5% | Both the 5% to < 10% and the ≥ 10% groups did significantly better than women who gained weight[23] |
| 5–10% | Total episodes fell 53%, 63% and 63% at 6, 12 and 18 months; about 3.7 times the odds of a ≥ 70% reduction at 12 months[23] |
| ≥ 10% | Total-episode reductions of 52%, 64% and 66% at 6, 12 and 18 months; greater benefit than with 5% to < 10% loss was not established[23] |
| Each 1 kg | In a pooled-arm Look AHEAD analysis of women with type 2 diabetes, each kilogram lost was associated with 3% lower odds of incident UI at 1 year; 5% to 10% loss was associated with 47% lower odds than <5% loss[9] |
A separate Look AHEAD analysis of 1,910 overweight or obese men with type 2 diabetes found that intensive lifestyle intervention (weight loss 9.4% versus 0.7% with diabetes support and education at 1 year, p < 0.001) lowered urinary incontinence prevalence from 11.3% to 9.0%, while prevalence rose from 9.7% to 11.6% with diabetes support and education alone. Intensive lifestyle intervention was also associated with higher odds of incontinence resolving (OR 1.93, 95% CI 1.04–3.59, p = 0.04; 56.0% versus 40.7%, p = 0.03) and a nonsignificant trend toward lower odds of new-onset incontinence.[24]
The AUGS systematic review (Yazdany 2020; 43 publications from 39 studies, including 5 randomized trials) found high-certainty evidence that behavioral weight loss lowers SUI prevalence by 15–18% and total UI prevalence by 12–17% at 1–2.9 years.[12] Certainty was moderate to low for urgency UI and OAB symptoms and lower for long-term effects.[12] The 2015 Cochrane review found low-quality evidence from one trial that more women in weight-loss programs reported improvement at 6 months (163/214 [76%] vs 49/90 [54%]), sustained at 18 months among 291 assessed women (75% vs 62%).[6] It concluded that evidence was insufficient to inform practice reliably.[6]
Bariatric Surgery — Large Observational Improvements
Bariatric surgery produces greater weight loss than behavioral programs, and cohort studies report large improvements in incontinence. Randomized data are limited to one small trial (n = 60) against a diet group.[12][18]
LABS-2 (Subak 2015)[5]
Of 2,458 LABS-2 participants, 1,987 (80.8%; 78.8% women) completed baseline and follow-up assessments; the cohort was assessed annually for up to 3 years after bariatric surgery:[5]
- Baseline weekly UI prevalence. 49.3% in women and 21.8% in men.[5]
- After a mean 29.5% 1-year weight loss in women, weekly UI prevalence fell to 18.3% (p < 0.001).[5]
- Weekly UI prevalence at 3 years was 24.8% in women, higher than at 1 year and lower than baseline.[5] Each 5% of weight loss was associated with remission of weekly UI (RR 1.08 in women).[5]
Meta-analyses
| Study | n | Follow-up | UI improvement / resolution |
|---|---|---|---|
| Lee 2019[13] | 2,910 (33 cohort) | median 12 mo | Any UI 56%; SUI 47%, UUI 53%; ICIQ −4.0; 3% worse / new-onset; evidence quality very low |
| Hadizadeh 2026[14] | 5,299 (32 prospective) | variable | UI prevalence ↓ 50%; SUI and UUI both improved; FI unchanged; POP improved |
| Waeckel 2023[15] | 67 of 83 (prospective) | 6 yr | SUI improved and sustained at 6 yr; OAB improved but less than at 1 yr |
In the 2026 Hadizadeh meta-analysis, fecal incontinence outcomes were unchanged despite gains in UI and POP.[14]
Effect on Anti-Incontinence Surgery Outcomes
The ICI-RS 2018 consensus concluded that the success rate of anti-incontinence surgery does not appear greatly affected by BMI, although reliable long-term data are lacking.[3] In the Greer 2008 meta-analysis of tension-free vaginal tape (TVT) for SUI, pooled cure rates were 81% in 453 obese and 85% in 1,186 nonobese women (P < .001; OR 0.576, 95% CI 0.426–0.779).[16] Bladder-perforation rates were lower in obese women (1.2% vs 6.6%, p = 0.015).[16]
Practical implication. Counsel overweight or obese women with bothersome SUI that weight loss may improve leakage .[25] Start other non-surgical pelvic floor care without waiting for weight loss, as NICE NG210 advises.[28] Obesity alone does not preclude continence surgery after conservative treatment, but the CUA recommends delaying SUI surgery in women considering bariatric surgery .[10][16][25]
GLP-1 Receptor Agonists — Emerging Signal
No randomized trial has studied GLP-1 agonists with incontinence as a primary outcome. Weight loss with semaglutide 2.4 mg plus lifestyle intervention in adults with overweight or obesity without diabetes was about 15% at 68 weeks (STEP 1), above the 5–10% range associated with UI improvement in the PRIDE secondary analysis.[19][23]
In a retrospective TriNetX cohort (Hammad 2025), concurrent GLP-1 agonist use in non-diabetic OAB patients undergoing onabotulinumtoxinA was associated with less new urinary retention (37/751 [4.9%] vs 67/780 [8.6%], p = 0.0044) and fewer new UTIs (43/488 [8.8%] vs 69/517 [13.3%], p = 0.0224) than BTX-A alone after propensity matching (992 per group, adjusted for BMI among other factors); each analysis excluded patients with the corresponding prior event.[20] Whether this reflects weight loss, direct GLP-1 receptor effects on bladder function, or other mechanisms is unclear.
Fecal Incontinence — Less Robust Benefit
Weight loss has a weaker effect on fecal incontinence than on UI.[14][17][18]
- Markland 2011. FI severity improved in 45 women across time points; 291 of 338 PRIDE participants completed follow-up. The randomized groups did not differ in FI improvement, so the authors analyzed FI as a follow-up cohort.[17] Improved liquid-stool FI was associated with ≥ 5 kg weight loss (p = 0.001) and increased dietary fiber (p = 0.05).[17]
- Hadizadeh 2026. The bariatric meta-analysis found no significant change in FI outcomes after surgery.[14]
- Güneş 2023. In this randomized study of sleeve gastrectomy versus diet (n = 60), the Wexner score improved after surgery, but the correlation between %TWL and FI was the weakest among all pelvic-floor outcomes.[18]
Stool consistency has been proposed as a contributor to FI in obesity, in contrast to the mechanical and inflammatory mechanisms proposed for UI.[4]
For the dietary-modification side of FI management, see ACOG PB 210.[2]
Practical Targets
| Target | Expected UI benefit | Evidence |
|---|---|---|
| ≥ 5% body weight | Significantly greater reduction in UI episodes than weight gain | PRIDE secondary analysis[23] |
| 5–10% body weight | In a pooled PRIDE secondary analysis, women losing 5% to < 10% had 53%, 63% and 63% fewer total UI episodes at 6, 12 and 18 months (versus 11%, 31% and 40% with weight gain); separately, an AUGS review found SUI prevalence 15–18% lower with behavioral weight loss overall at 1–2.9 yr | PRIDE / AUGS SR[23][12] |
| ≥ 10% body weight | Greater benefit than with 5% to <10% loss was not demonstrated | Pooled PRIDE secondary analysis[23] |
| ~ 30% body weight (bariatric) | In LABS-2, women averaged 29.5% weight loss at 1 yr as weekly UI prevalence fell from 49.3% to 18.3%; separately, a prospective-study meta-analysis found UI prevalence 50% lower after bariatric surgery without a 30%-loss subgroup estimate | Hadizadeh[14]; LABS-2 (women 49.3% to 18.3% at 1 yr)[5] |
| Each 1 kg | 3% lower odds of developing UI (women with type 2 diabetes, 1 yr) | Look AHEAD[9] |
Guideline Summary
| Organization | Recommendation |
|---|---|
| ACOG PB 155 (2015)[1] | Moderate weight loss improves UI in overweight / obese women; even ~ 8% weight loss is effective |
| JAMA Lukacz 2017[8] | Initial management includes lifestyle modifications, which can include weight loss |
| NEJM Wu 2021[7] | 5–10% reduction yields modest improvements in SUI at 1–3 yr |
| AUGS Yazdany 2020[12] | High-certainty evidence: SUI prevalence 15–18% lower and total UI 12–17% lower with behavioral weight loss at 1–2.9 yr |
| ICI-RS 2018[3] | Weight reduction positively correlated with UI improvement; should be advocated |
| Cochrane Imamura 2015[6] | Low-quality evidence that weight-loss programs improve UI; insufficient evidence to inform practice reliably |
| CUA 2024[25] | Counsel overweight or obese women with bothersome SUI that weight loss may improve leakage (Strong; high-quality evidence); delay SUI surgery for women considering bariatric surgery (Strong; moderate-quality evidence) |
| EAU 2026[26] | Encourage overweight or obese women with LUTS/SUI to lose weight and maintain the loss ; inform women with obesity and SUI of greater surgical risk and lower probability of benefit |
Synthesis — Where Weight Loss Fits
- Consider as initial conservative therapy for women with BMI ≥ 25 and incontinence; ICI-RS advocates weight reduction and Subak 2009 recommends it be strongly considered first line.[3][10] 2.[23] 5% to < 10% body weight was associated with greater reductions in weekly UI episodes than weight gain in the pooled PRIDE analysis; weight-loss categories were not randomized.[23]
- Sustained loss. In PRIDE, between-group differences in stress and total UI were no longer significant at 18 months as mean intervention weight loss fell to 5.5%. In LABS-2's 1,565-woman bariatric-surgery analysis (1,373 assessed at year 1 and 1,188 at year 3), modeled prevalence of at least weekly UI rose from 18.3% at 1 year to 24.8% at 3 years.[5][22]
- SUI greater than UUI in magnitude and consistency of effect; FI benefit is limited and inconsistent.
- Bariatric surgery is associated with a UI prevalence about 50% lower in a meta-analysis of prospective studies, and one small cohort found SUI improvement sustained at 6 years.[14][15]
- Obesity does not preclude surgery. Anti-incontinence surgery remains an option for women with obesity;[3] a 2008 TVT meta-analysis found cure rates of 81% versus 85% in women without obesity.[16] The EAU 2026 guideline recommends informing women with obesity and SUI about increased surgical risks and a lower probability of benefit .[26]
- GLP-1 agonists have not been studied in randomized trials for incontinence.
Summary
Weight loss is a conservative treatment for female urinary incontinence supported by randomized evidence. In the PRIDE 2009 NEJM RCT, about 8% behavioral weight loss reduced weekly UI episodes by 47% (versus 28% in controls), with the clearest effect on stress incontinence.[11] The LABS-2 bariatric cohort showed UI prevalence in women falling from 49.3% to 18.3% after a mean 29.5% weight loss at 1 year, and 24.8% at 3 years.[5] In a post-randomization PRIDE analysis, 5% to <10% weight loss was associated with fewer UI episodes than weight gain, without clear additional benefit at ≥10% loss.[23] In the randomized comparison, stress-UI episode frequency improved more with intervention through 12 months; at 18 months, stress and total UI differences were not significant as controls improved, while a ≥70% reduction in weekly urge episodes favored intervention (47% versus 34%).[22] The fecal-incontinence benefit is smaller.[14][17] Weight-management counseling should be strongly considered as initial care for women with BMI ≥ 25 and incontinence.[3][10]
References
1. ACOG Practice Bulletin No. 155: urinary incontinence in women. Obstet Gynecol. 2015;126(5):e66-e81. doi:10.1097/AOG.0000000000001148.
2. ACOG Practice Bulletin No. 210: fecal incontinence. Obstet Gynecol. 2019;133(4):e260-e273. doi:10.1097/AOG.0000000000003187.
3. Marcelissen T, Anding R, Averbeck M, et al. Exploring the relation between obesity and urinary incontinence: pathophysiology, clinical implications, and the effect of weight reduction, ICI-RS 2018. Neurourol Urodyn. 2019;38 Suppl 5:S18-S24. doi:10.1002/nau.24072.
4. Doumouchtsis SK, Loganathan J, Pergialiotis V. The role of obesity on urinary incontinence and anal incontinence in women: a review. BJOG. 2022;129(1):162-170. doi:10.1111/1471-0528.16848.
5. Subak LL, King WC, Belle SH, et al. Urinary incontinence before and after bariatric surgery. JAMA Intern Med. 2015;175(8):1378-1387. doi:10.1001/jamainternmed.2015.2609.
6. Imamura M, Williams K, Wells M, McGrother C. Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database Syst Rev. 2015;(12):CD003505. doi:10.1002/14651858.CD003505.pub5.
7. Wu JM. Stress incontinence in women. N Engl J Med. 2021;384(25):2428-2436. doi:10.1056/NEJMcp1914037.
8. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592-1604. doi:10.1001/jama.2017.12137.
9. Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol. 2012;187(3):939-944. doi:10.1016/j.juro.2011.10.139.
10. Subak LL, Richter HE, Hunskaar S. Obesity and urinary incontinence: epidemiology and clinical research update. J Urol. 2009;182(6 Suppl):S2-S7. doi:10.1016/j.juro.2009.08.071.
11. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481-490. doi:10.1056/NEJMoa0806375.
12. Yazdany T, Jakus-Waldman S, Jeppson PC, et al. American Urogynecologic Society systematic review: the impact of weight loss intervention on lower urinary tract symptoms and urinary incontinence in overweight and obese women. Female Pelvic Med Reconstr Surg. 2020;26(1):16-29. doi:10.1097/SPV.0000000000000802.
13. Lee Y, Yu J, Tikkinen KAO, et al. The impact of bariatric surgery on urinary incontinence: a systematic review and meta-analysis. BJU Int. 2019;124(6):917-934. doi:10.1111/bju.14829.
14. Hadizadeh A, Chill HH, Leffelman A, et al. Impact of bariatric surgery on pelvic floor dysfunction symptoms: a systematic review and meta-analysis of prospective studies. Surg Obes Relat Dis. 2026. doi:10.1016/j.soard.2026.03.018.
15. Waeckel T, Ait Said K, Menahem B, et al. Urinary continence resolution after bariatric surgery: long-term results after six-year follow-up. J Clin Med. 2023;12(6):2109. doi:10.3390/jcm12062109.
16. Greer WJ, Richter HE, Bartolucci AA, Burgio KL. Obesity and pelvic floor disorders: a systematic review. Obstet Gynecol. 2008;112(2 Pt 1):341-349. doi:10.1097/AOG.0b013e31817cfdde.
17. Markland AD, Richter HE, Burgio KL, et al. Weight loss improves fecal incontinence severity in overweight and obese women with urinary incontinence. Int Urogynecol J. 2011;22(9):1151-1157. doi:10.1007/s00192-011-1444-x.
18. Güneş Y, Fersahoğlu MM, Bulut NE, et al. Effects of sleeve gastrectomy on pelvic floor disorders in female patients with severe obesity: a prospective study. Obes Surg. 2023;33(10):3069-3076. doi:10.1007/s11695-023-06725-w.
19. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
20. Hammad MAM, Quesada SG, Belczyk AL, Ghoniem GM. Beyond glycemic control: concurrent GLP-1 receptor agonist use is associated with reduced urinary adverse events following onabotulinumtoxinA treatment in non-diabetic adults with overactive bladder. Toxins. 2025;17(11):542. doi:10.3390/toxins17110542.
21. Brown JS, Wing R, Barrett-Connor E, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care. 2006;29(2):385-390. doi:10.2337/diacare.29.02.06.dc05-1781.
22. Wing RR, West DS, Grady D, et al. Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months. J Urol. 2010;184(3):1005-1010. doi:10.1016/j.juro.2010.05.031.
23. Wing RR, Creasman JM, West DS, et al. Improving urinary incontinence in overweight and obese women through modest weight loss. Obstet Gynecol. 2010;116(2 Pt 1):284-292. doi:10.1097/AOG.0b013e3181e8fb60.
24. Breyer BN, Phelan S, Hogan PE, et al. Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: results from the Look AHEAD trial. J Urol. 2014;192(1):144-9. doi:10.1016/j.juro.2014.02.036.
25. Carlson K, Andrews M, Bascom A, et al. "2024 Canadian Urological Association guideline: Female stress urinary incontinence." Can Urol Assoc J. 2024;18(4):83-102. doi:10.5489/cuaj.8751
26. European Association of Urology. EAU Guidelines on Non-neurogenic Female LUTS: Disease Management. EAU Guidelines Office; 2026. Guideline
27. Todhunter-Brown A, Hazelton C, Campbell P, Elders A, Hagen S, McClurg D. "Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews." Cochrane Database Syst Rev. 2022;2022(9):CD012337. doi:10.1002/14651858.CD012337.pub2
28. National Institute for Health and Care Excellence. Pelvic floor dysfunction: prevention and non-surgical management (NG210). 2021. Recommendations.